The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preser...

Descripción completa

Detalles Bibliográficos
Autores principales: McADAM, LAURA C., MAYO, AMANDA L., ALMAN, BENJAMIN A., BIGGAR, W. DOUGLAS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SpA 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440807/
https://www.ncbi.nlm.nih.gov/pubmed/22655512
_version_ 1782243192867913728
author McADAM, LAURA C.
MAYO, AMANDA L.
ALMAN, BENJAMIN A.
BIGGAR, W. DOUGLAS
author_facet McADAM, LAURA C.
MAYO, AMANDA L.
ALMAN, BENJAMIN A.
BIGGAR, W. DOUGLAS
author_sort McADAM, LAURA C.
collection PubMed
description Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.
format Online
Article
Text
id pubmed-3440807
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Pacini Editore SpA
record_format MEDLINE/PubMed
spelling pubmed-34408072012-10-12 The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy McADAM, LAURA C. MAYO, AMANDA L. ALMAN, BENJAMIN A. BIGGAR, W. DOUGLAS Acta Myol Original Articles Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy. Pacini Editore SpA 2012-05 /pmc/articles/PMC3440807/ /pubmed/22655512 Text en The journal and the individual contributions contained in it are protected by the copyright of Gaetano Conte Academy, Naples, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Articles
McADAM, LAURA C.
MAYO, AMANDA L.
ALMAN, BENJAMIN A.
BIGGAR, W. DOUGLAS
The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title_full The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title_fullStr The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title_full_unstemmed The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title_short The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
title_sort canadian experience with long term deflazacort treatment in duchenne muscular dystrophy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440807/
https://www.ncbi.nlm.nih.gov/pubmed/22655512
work_keys_str_mv AT mcadamlaurac thecanadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT mayoamandal thecanadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT almanbenjamina thecanadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT biggarwdouglas thecanadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT mcadamlaurac canadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT mayoamandal canadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT almanbenjamina canadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy
AT biggarwdouglas canadianexperiencewithlongtermdeflazacorttreatmentinduchennemusculardystrophy

Ejemplares similares